Novo Nordisk Halts Two Trials of Inflammation-Reducing Drug for Heart Health

In a significant setback for cardiovascular innovation, Novo Nordisk has announced the discontinuation of two critical trials aimed at evaluating the efficacy of ziltivekimab, a drug designed to combat inflammation and improve heart health.

The HERMES and ATHENA trials were halted after a data monitoring committee determined that the chances for success were slim. This news was conveyed to trial investigators on Friday, marking a pivotal moment in the company's research efforts.

This decision follows the disappointing results from the ZEUS trial, which previously indicated that while ziltivekimab effectively reduced inflammation markers, it failed to mitigate major clinical events such as heart attacks and fatalities.

Source: www.statnews.com